Apellis reports preliminary SYFOVRE Q3 revenue ~$74M; total since launch ~$160M

Apellis Pharmaceuticals, Inc.

2023-Q3 EPS reported -$3.73 revenue$250,214,000

Approximately $74M in preliminary US net SYFOVRE revenue for Q3 2023; ~$160M total since March 2023 launch.
More than 100,000 vials (commercial+sample) distributed to date; ~37,000 commercial and 10,000 samples in Q3.
Permanent J-code effective Oct 1; >95% of Medicare payers now covering SYFOVRE.
GALE extension study shows up to 45% reduction in nonsubfoveal GA lesion growth at Months 24-30 vs projected sham.
Estimated retinal vasculitis rate remains rare at 0.01% per injection; 10 confirmed events, 2 suspected.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apellis Pharmaceuticals, Inc. reported third quarter of 2023 results: revenue approximately $74 million.

Period: third quarter of 2023
Revenue: approximately $74 million
Result: preliminary results

Exact text from the filing

Apellis expects approximately $74 million in preliminary U.S. net product revenue for SYFOVRE in the third quarter and approximately $160 million in preliminary total U.S. net product revenue for SYFOVRE since launch in March 2023 through September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-251073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.